Skip to main content
Home
Zeitschriften
Zeitungen
Podcast
Gesundheitspolitik
Praxis
Allerlei
Jobs
Fachgebiete
Allgemeinmedizin Anästhesiologie & Intensivmedizin Apotheke Augenheilkunde Chirurgie Dermatologie Gynäkologie und Geburtshilfe HNO Innere Medizin Kinder & Jugendheilkunde Neurologie & Psychiatrie Orthopädie & Unfallchirurgie Pflege Urologie Zahnmedizin
Subfächer Innere Medizin
Diabetologie Gastroenterologie Infektiologie Kardiologie Onkologie und Hämatologie Pneumologie Rheumatologie
Fortbildungen
Überblick Fortbildungen DFP-Literaturstudium-Artikel DFP-Webcast Fortbildungen DFP-Podcasts
Erweiterte Suche
Anmelden
nach oben
memo - Magazine of European Medical Oncology
Erschienen in:

01.02.2023 | editorial

Best of hematology—2021

verfasst von: PD DDr. Katharina Theresa Prochazka

Erschienen in: memo - Magazine of European Medical Oncology | Ausgabe 1/2023

Einloggen, um Zugang zu erhalten

Auszug

The past year held a multitude of challenges for all of us. This was due to the additional workload in the care of patients with coronavirus disease 2019 (COVID-19) as well as the changed routine for our hematological patients. It is therefore all the more important to emphasize that despite this additional workload, research in Austria has continued to produce outstanding results. More than 1500 scientific articles have been published in more than 500 journals, ranging from immensely important basic research to internationally widely cited reviews [1]. …
Vorheriger Artikel Surgical management of liver metastasis from colorectal cancer
Nächster Artikel Update on systemic therapy for clear cell renal cell carcinoma
Literatur
1.
Hilbe W, et al. Österreichischer Krebsreport 2021. Verlag und Mediaservice Ges.m.b.H: MedMedia; 2022. OeGHO und Österreichische Krebshilfe.
2.
Bernard E, et al. Molecular international prognosis scoring system for myelodysplastic syndromes. ASH 2021. Oral and Poster Abstracts. 2021.
3.
Komrokji RS, et al. Assessing the role of Venetoclax in combination with hypomethylating agents in higher risk myelodysplastic syndromes. ASH 2021. Oral and Poster Abstracts. 2021.CrossRef
4.
Bazinet A, et al. A phase I/II study of Venetoclax in combination with 5‑azacytidine in treatment-naïve and relapsed/refractory high-risk myelodysplastic syndrome (MDS) or chronic Myelomonocytic leukemia (CMML). ASH 2021. Oral and Poster Abstracts. 2021.CrossRef
5.
Zeidan AM, et al. Immune and Epigenetic Landscape of TP53-mutated Acute Myeloid Leukemia (AML) and Higher-Risk Myelodysplastic Syndromes (HR-MDS) ASH 2021. Oral and Poster Abstracts. 2021.
6.
Garcia JS, et al. Molecular responses are observed across mutational spectrum in treatment-naïve higher-risk myelodysplastic syndrome patients treated with Venetoclax plus Azacitidine. ASH 2021. Oral and Poster Abstracts. 2021.CrossRef
7.
Goldschmidt H, et al. Addition of Isatuximab to lenalidomide, bortezomib and dexamethasone as induction therapy for newly-diagnosed, transplant-eligible multiple myeloma patients: the phase III GMMG-HD7 trial. ASH 2021. Oral and Poster Abstracts. 2021.
8.
Costa L, et al. Thalassemia and Globin gene regulation poster I. ASH 2021. Oral and Poster Abstracts. 2021.
9.
Moreau P, et al. Updated results from MajesTEC-1: phase 1/2 study of teclistamab, a B-cell maturation antigen x CD3 bispecific antibody, in relapsed/refractory multiple myeloma. ASH 2021. Oral and Poster Abstracts. 2021.
10.
Martin T, et al. Updated results from CARTITUDE-1: phase 1b/2study of ciltacabtagene autoleucel, a B-cell maturation antigen-directed chimeric antigen receptor T cell therapy, in patients with relapsed/refractory multiple myeloma. ASH 2021. Oral and Poster Abstracts. 2021.
11.
Haferlach C, et al. Benchmarking of whole genome sequencing (WGS) and whole transcriptome sequencing (WTS) as diagnostic tools for the genetic characterization of acute Myeloid leukemia (AML) and acute Lymphoblastic leukemia (ALL) in adults. ASH 2021. Oral and Poster Abstracts. 2021.CrossRef
12.
Mutter JA, et al. Profiling of circulating tumor DNA for noninvasive disease detection, risk stratification, and MRD monitoring in patients with CNS Lymphoma. ASH 2021. General Sessions.. 2021.CrossRef
13.
Tilly H, et al. Polatuzumab vedotin in previously untreated diffuse large B‑cell lymphoma. N Engl J Med. 2022;386:351–63.CrossRefPubMed
14.
Budde E, et al. Mosunetuzumab monotherapy is an effective and well-tolerated treatment option for patients with relapsed/refractory (R/R) follicular lymphoma (FL) who have received ≥2 prior lines of therapy: pivotal results from a phase I/II study. ASH 2021. Oral and Poster Abstracts. 2021.
15.
Morschhauser F, et al. Mosunetuzumab in combination with lenalidomide has a manageable safety profile and encouraging activity in patients with relapsed/refractory follicular Lymphoma: initial results from a phase Ib study. ASH 2021. Oral and Poster Abstracts. 2021.
16.
Locke FL, et al. Axicabtagene ciloleucel as second-line therapy for large B‑cell lymphoma. N Engl J Med. 2022;386:640–54.CrossRefPubMed
17.
Bishop MR, et al. Second-line tisagenlecleucel or standard care in aggressive B‑cell lymphoma. N Engl J Med. 2022;386:629–39.CrossRefPubMed
18.
Kamdar M et al. Lisocabtagene Maraleucel (liso-cel), a CD19-Directed Chimeric Antigen Receptor (CAR) T Cell Therapy, Versus Standard of Care (SOC) with Salvage Chemotherapy (CT) Followed By Autologous Stem Cell Transplantation (ASCT) As Second-Line (2L) Treatment in Patients (Pts) with Relapsed or Refractory (R/R) Large B‑Cell Lymphoma (LBCL): Results from the Randomized Phase 3 Transform Study. ASH 2021. Oral and Poster Abstracts.
19.
Guetl K, et al. SARS-CoV‑2 vaccine-induced immune thrombotic thrombocytopenia treated with immunoglobulin and argatroban. Lancet. 2021;397(10293):e19.CrossRefPubMedPubMedCentral
20.
Maillard A, et al. Antibody response after 2 and 3 doses of SARS-CoV‑2 mRNA vaccine in allogeneic hematopoietic cell transplant recipients. Blood. 2022;139(1):134–7.CrossRefPubMed
21.
Herishanu Y, et al. Efficacy of the BNT162b2 mRNA COVID-19 vaccine in patients with chronic lymphocytic leukemia. Blood. 2021;137(23):3165–73.CrossRefPubMedPubMedCentral
22.
Schulz E, et al. CD19+IgD+CD27− Naïve B cells as predictors of humoral response to COVID 19 mRNA vaccination in immunocompromised patients. Front Immunol. 2022;12:803742.CrossRef
Metadaten
Titel
Best of hematology—2021
verfasst von
PD DDr. Katharina Theresa Prochazka
Publikationsdatum
01.02.2023
Verlag
Springer Vienna
Erschienen in
memo - Magazine of European Medical Oncology / Ausgabe 1/2023
Print ISSN: 1865-5041
Elektronische ISSN: 1865-5076
DOI
https://doi.org/10.1007/s12254-022-00826-5

Weitere Artikel der Ausgabe 1/2023

Dual immune checkpoint blockade in gastroesophageal tumors: never say never

  • Open Access
  • short review

Total neoadjuvant therapy in rectal cancer

  • short review

Biomarkers and translational research approaches in breast cancer—an update

  • Open Access
  • short review

Vaccination against SARS-CoV-2 in adults with a diagnosis of cancer: a short review

  • short review

Colorectal cancer special, part 1

  • editorial

Hodgkin lymphoma—how much therapy do we need?

  • short review